|Bid||102.90 x 1300|
|Ask||105.22 x 1000|
|Day's Range||104.29 - 105.21|
|52 Week Range||85.00 - 122.28|
|Beta (3Y Monthly)||1.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||126.72|
Mechelen, Belgium; 8 January 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Sands Capital.
7 January 2019, 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) initiated a Phase 1 trial with GLPG3312, a first generation compound against a novel and undisclosed inflammation target class discovered by Galapagos. "We are excited by the rapid progression of our Toledo program into the clinic," said Dr. Piet Wigerinck, Chief Scientific Officer at Galapagos.
6 January 2019, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program with '1690 in IPF. NOVESA is a double-blind, placebo-controlled Phase 2a trial evaluating the efficacy, safety and PK/PD of '1690 in patients with systemic sclerosis (SSc, or scleroderma). NOVESA is planned to recruit 30 patients with diffuse cutaneous SSc, an autoimmune disease involving multiorgan fibrosis, which has one of the highest mortality rates among rheumatic diseases.
4 January 2019, 22.01 CET - Fibrocor Therapeutics L.P. (Fibrocor), a privately held Canadian company, and Galapagos NV (Euronext & NASDAQ: GLPG) announced a global partnership focused on a novel target for idiopathic pulmonary fibrosis (IPF) and other indications. In exchange for global commercialization rights to Galapagos, Fibrocor will receive an upfront payment, and potentially is eligible for further milestone and royalty payments. Galapagos will be responsible for all further development of the program.
In 1999 Onno van de Stolpe was appointed CEO of Galapagos NV (AMS:GLPG). First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at Read More...
Mechelen, Belgium; 21 December 2018, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 37th Annual J.P. Morgan Healthcare Conference on January 8.
17 December 2018, 22.15 CET - Galapagos NV (Euronext & NASDAQ: GLPG) today announces that it has dosed its first patient in the worldwide ISABELA Phase 3 program with autotaxin inhibitor GLPG1690 in IPF. "Today's news again demonstrates our commitment to the rapid advancement of our IPF franchise, including the ISABELA and the PINTA trials. GLPG1690 is a small molecule, selective autotaxin inhibitor which is fully proprietary to Galapagos.
NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
27 November 2018, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that the FDA has granted GLPG1972/S201086 Fast Track designation for the treatment of patients with osteoarthritis (OA). The US Food and Drug Administration's (FDA's) Fast Track program is designed to facilitate the development and expedite the review of drugs that treat serious or life-threatening diseases or conditions and that demonstrate the potential to address unmet medical needs. Drugs that receive this designation are eligible for more frequent interactions with the FDA and are potentially eligible for priority review and rolling review of a New Drug Application (NDA).
When it comes to biotech stocks, the perception is that the sector is a gamble. Many investors believe that most biotech stocks are clinical-stage lotto tickets that will only succeed on a wish and a prayer. It’s here that investors can find stable cash flows, profits, and even dividend stocks.
Mechelen, Belgium; 26 November 2018; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Van Herk Investments.
Mechelen, Belgium; 23 November 2018, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant.
Galapagos (GLPG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PINTA is a randomized, double-blind, placebo-controlled Phase 2 trial investigating a 100 mg once-daily oral dose of GLPG1205 in up to 60 IPF patients. "The first patient dosing in our PINTA Phase 2 trial shows the progress we are making in expanding our IPF franchise," said Dr. Piet Wigerinck, Chief Scientific Officer at Galapagos.
NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Galapagos NV (AMS:GLPG), with a market capitalization of €4.9b, rarely draw their attention from the investing community. Read More...
NORTH CHICAGO, Ill., Oct. 24, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, announced today that it will assume full development and commercial responsibility for its collaboration with Galapagos (GLPG.NX) to discover and develop new therapies to treat cystic fibrosis (CF). AbbVie's research program aims to develop a best-in-class, triple-combination therapy for patients living with cystic fibrosis. Currently in early clinical development, the program consists of mechanistically distinct drug-candidates, termed "potentiators" and "correctors", which collectively increase the activity of the mutated copies of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that causes CF.
First nine months financial results: Group revenues increased by €98.7 million to €205.1 million Operating loss decreased by €9.1 million to €53.5 million Net loss.
AbbVie takes over all programs in CF and continues the development of a triple combination therapy for CF. AbbVie will obtain exclusive worldwide rights to the current CF investigational drug candidate portfolio developed by the two companies in the course of the collaboration. AbbVie will be responsible for all future activities and will bear all costs associated with this portfolio in CF going forward.
The FALCON trial is a phase 1b, multi-center, open-label, non-randomized, multiple cohorts study to assess the safety, tolerability, pharmacokinetics, and efficacy of a novel combination treatment of GLPG2451 and GLPG2222, with and without GLPG2737, in up to 24 adult patients with CF. The FALCON study's primary objectives include safety and PK. Secondary objectives include changes in pharmacodynamic biomarkers for CFTR activity (sweat chloride concentration and ppFEV1).
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis and ankylosing spondylitis were both published in The Lancet. “The results of the EQUATOR and TORTUGA studies demonstrate that filgotinib improved the signs and symptoms of patients with psoriatic arthritis whose disease had not responded to prior therapies and independently, for those with ankylosing spondylitis,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences.